Alpha Tau Medical (NASDAQ:DRTS) Shares Down 0.3% - Here's Why

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) were down 0.3% during mid-day trading on Thursday . The company traded as low as $3.01 and last traded at $3.06. Approximately 43,453 shares traded hands during mid-day trading, a decline of 12% from the average daily volume of 49,258 shares. The stock had previously closed at $3.07.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, April 29th.

Alpha Tau Medical Stock Down 2.0%

The stock's 50 day moving average price is $3.03 and its 200-day moving average price is $2.99. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.81 and a current ratio of 5.81. The company has a market cap of $252.76 million, a PE ratio of -6.48 and a beta of 0.99.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its quarterly earnings results on Monday, May 19th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. On average, analysts predict that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DRTS. Kovitz Investment Group Partners LLC lifted its position in Alpha Tau Medical by 601.4% during the first quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock valued at $568,000 after acquiring an additional 194,055 shares during the last quarter. Renaissance Technologies LLC increased its stake in Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after buying an additional 26,800 shares during the period. Northern Trust Corp increased its position in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock valued at $151,000 after purchasing an additional 25,770 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Alpha Tau Medical during the 1st quarter worth $53,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.